RxDoctor Payments Data

Joseph Dunn, MD

Interventional Pain Medicine · Eugene, ORNPI 1831125616

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,031 of the $9,510 with a category attached, or 73.9%. 24 manufacturers reported payments, led by Boston Scientific at 24.9% of the total.

$9,510in general payments, 2019–2025

Across 286 payments — averaging $33.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Relievant Medsystems, Inc.$2K
  • Medtronic$1K
  • Nevro Corp.$868
  • Nalu Medical, Inc.$817
  • Protega Pharmaceutials Inc$700
  • plus $2K from 18 others

What the payments were for

  • Speaking & faculty fees$7007%
  • Travel & lodging$1,74818%
  • Food & beverage$7,03174%
  • Education$310%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,510 in reported general payments places this provider in the 60th percentile of 22 interventional pain medicine providers in Oregon.

See all interventional pain medicine providers in Oregon

Medicare billing

Part B allowed, 2024
$292,790
Medicare patients
285
Services billed
2,353

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxycontinOxycodone Hcl52$20,680
NucyntaTapentadol Hcl15$11,711
Oxycodone Hcl528$11,614
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen414$10,456
Fentanyl90$9,611
Oxymorphone Hcl ErOxymorphone Hcl17$8,876
Naloxone Hcl134$8,729
Buprenorphine21$8,563
Morphine Sulfate ErMorphine Sulfate140$7,069
Buprenorphine Hcl120$6,314
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen153$3,513
Methadone Hcl183$3,219
Tizanidine Hcl222$3,215
Gabapentin176$2,796
Hydromorphone Hcl173$2,700

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Eugene

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →